Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1979 Aug;8(2):115–124. doi: 10.1111/j.1365-2125.1979.tb05809.x

The characteristics of the binding of 12-alpha-[3H]-digoxin to the membranes of intact human erythrocytes: relevance to digoxin therapy.

A R Ford, J K Aronson, D G Grahame-Smith, J A Rose
PMCID: PMC1429769  PMID: 486288

Abstract

1 The characteristics of the binding of 12-alpha-[3H]-digoxin to the membranes of intact human erythrocytes are described. 2 Only one class of binding site can be demonstrated. Binding is time- and temperature-dependent, saturable and slowly reversible; it is inhibited by other cardiac glycosides and by potassium. 3 Pre-incubation with unlabelled digoxin reduces the subsequent binding of 12-alpha-[3H]-digoxin in stoichiometric fashion. 4 The possible application of the measurement of the binding of 12-alpha-[3H]-digoxin to the study of biochemical pharmacological events occurring during digoxin therapy is discussed.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akera T. Membrane adenosinetriphosphatase: a digitalis receptor? Science. 1977 Nov 11;198(4317):569–574. doi: 10.1126/science.144320. [DOI] [PubMed] [Google Scholar]
  2. Aronson J. K., Grahame-Smith D. G., Hallis K. F., Hibble A., Wigley F. Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response. Br J Clin Pharmacol. 1977 Apr;4(2):213–221. doi: 10.1111/j.1365-2125.1977.tb00697.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Aronson J. K., Grahame-Smith D. G. Monitoring digoxin therapy: II. Determinants of the apparent volume of distribution. Br J Clin Pharmacol. 1977 Apr;4(2):223–227. doi: 10.1111/j.1365-2125.1977.tb00698.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Baker P. F., Willis J. S. Binding of the cardiac glycoside ouabain to intact cells. J Physiol. 1972 Jul;224(2):441–462. doi: 10.1113/jphysiol.1972.sp009904. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cheng Y., Prusoff W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973 Dec 1;22(23):3099–3108. doi: 10.1016/0006-2952(73)90196-2. [DOI] [PubMed] [Google Scholar]
  6. Ellory J. C., Keynes R. D. Binding of tritiated digoxin to human red cell ghosts. Nature. 1969 Feb 22;221(5182):776–776. doi: 10.1038/221776a0. [DOI] [PubMed] [Google Scholar]
  7. Erdmann E., Hasse W. Quantitative aspects of ouabain binding to human erythrocyte and cardiac membranes. J Physiol. 1975 Oct;251(3):671–682. doi: 10.1113/jphysiol.1975.sp011115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ford A. R., Aronson J. K., Grahame-Smith D. G., Carver J. G. Changes in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients receiving digoxin during the early phases of treatment of cardiac failure in regular rhythm and of atrial fibrillation. Br J Clin Pharmacol. 1979 Aug;8(2):125–134. doi: 10.1111/j.1365-2125.1979.tb05810.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ford A. R., Aronson J. K., Grahame-Smith D. G., Carver J. G. The acute changes seen in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients during the early phases of digoxin therapy are not found during chronic therapy: pharmacological and therapeutic implications for chronic digoxin therapy. Br J Clin Pharmacol. 1979 Aug;8(2):135–142. doi: 10.1111/j.1365-2125.1979.tb05811.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gardner J. D., Conlon T. P. The effects of sodium and potassium on ouabain binding by human erythrocytes. J Gen Physiol. 1972 Nov;60(5):609–629. doi: 10.1085/jgp.60.5.609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gardner J. D., Kilno D. R., Swartz T. J., Butler V. P., Jr Effects of digoxin-specific antibodies on accumulation and binding of digoxin by human erythrocytes. J Clin Invest. 1973 Aug;52(8):1820–1833. doi: 10.1172/JCI107364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Glynn I. M., Karlish S. J. The sodium pump. Annu Rev Physiol. 1975;37:13–55. doi: 10.1146/annurev.ph.37.030175.000305. [DOI] [PubMed] [Google Scholar]
  13. SCHATZMANN H. J. Herzglykoside als Hemmstoffe für den aktiven Kalium- und Natriumtransport durch die Erythrocytenmembran. Helv Physiol Pharmacol Acta. 1953;11(4):346–354. [PubMed] [Google Scholar]
  14. Schwartz A., Lindenmayer G. E., Allen J. C. The sodium-potassium adenosine triphosphatase: pharmacological, physiological and biochemical aspects. Pharmacol Rev. 1975 Mar;27(01):3–134. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES